Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Nuclear Quantum Effects in Hydrophobic Nanoconfinement.

Shrestha BR, Pillai S, Santana A, Donaldson SH Jr, Pascal TA, Mishra H.

J Phys Chem Lett. 2019 Sep 19;10(18):5530-5535. doi: 10.1021/acs.jpclett.9b01835. Epub 2019 Sep 6.

PMID:
31365261
2.

Multimodal Miniature Surface Forces Apparatus (μSFA) for Interfacial Science Measurements.

Kristiansen K, Donaldson SH Jr, Berkson ZJ, Scott J, Su R, Banquy X, Lee DW, de Aguiar HB, McGraw JD, Degen GD, Israelachvili JN.

Langmuir. 2019 Aug 9. doi: 10.1021/acs.langmuir.9b01808. [Epub ahead of print]

PMID:
31362502
3.

Interface-Sensitive Raman Microspectroscopy of Water via Confinement with a Multimodal Miniature Surface Forces Apparatus.

de Aguiar HB, McGraw JD, Donaldson SH Jr.

Langmuir. 2019 Jul 29. doi: 10.1021/acs.langmuir.9b01889. [Epub ahead of print]

PMID:
31310142
4.

Exercising our options: comparing effects of exercise and positive expiratory pressure on mucociliary clearance.

Donaldson SH.

Eur Respir J. 2019 Apr 18;53(4). pii: 1900510. doi: 10.1183/13993003.00510-2019. Print 2019 Apr. No abstract available.

PMID:
31000670
5.

MicroMegascope based dynamic surface force apparatus.

Lainé A, Jubin L, Canale L, Bocquet L, Siria A, Donaldson SH, Niguès A.

Nanotechnology. 2019 May 10;30(19):195502. doi: 10.1088/1361-6528/ab02ba. Epub 2019 Jan 29.

PMID:
30695757
6.

Jealousy, Consent, and Compersion Within Monogamous and Consensually Non-Monogamous Romantic Relationships.

Mogilski JK, Reeve SD, Nicolas SCA, Donaldson SH, Mitchell VE, Welling LLM.

Arch Sex Behav. 2019 Aug;48(6):1811-1828. doi: 10.1007/s10508-018-1286-4. Epub 2019 Jan 3.

PMID:
30607710
7.

Effect of ivacaftor on mucociliary clearance and clinical outcomes in cystic fibrosis patients with G551D-CFTR.

Donaldson SH, Laube BL, Corcoran TE, Bhambhvani P, Zeman K, Ceppe A, Zeitlin PL, Mogayzel PJ Jr, Boyle M, Locke LW, Myerburg MM, Pilewski JM, Flanagan B, Rowe SM, Bennett WD.

JCI Insight. 2018 Dec 20;3(24). pii: 122695. doi: 10.1172/jci.insight.122695.

8.

Beyond the expected: Identifying broad research priorities of researchers and the cystic fibrosis community.

Hollin IL, Donaldson SH, Roman C, Aliaj E, Riva D, Boyle M, Borowitz D.

J Cyst Fibros. 2019 May;18(3):375-377. doi: 10.1016/j.jcf.2018.11.010. Epub 2018 Nov 28.

PMID:
30503031
9.

An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases.

Ehre C, Rushton ZL, Wang B, Hothem LN, Morrison CB, Fontana NC, Markovetz MR, Delion MF, Kato T, Villalon D, Thelin WR, Esther CR Jr, Hill DB, Grubb BR, Livraghi-Butrico A, Donaldson SH, Boucher RC.

Am J Respir Crit Care Med. 2019 Jan 15;199(2):171-180. doi: 10.1164/rccm.201802-0245OC.

PMID:
30212240
10.

SPLUNC1 degradation by the cystic fibrosis mucosal environment drives airway surface liquid dehydration.

Webster MJ, Reidel B, Tan CD, Ghosh A, Alexis NE, Donaldson SH, Kesimer M, Ribeiro CMP, Tarran R.

Eur Respir J. 2018 Oct 4;52(4). pii: 1800668. doi: 10.1183/13993003.00668-2018. Print 2018 Oct.

11.

CFTR modulator theratyping: Current status, gaps and future directions.

Clancy JP, Cotton CU, Donaldson SH, Solomon GM, VanDevanter DR, Boyle MP, Gentzsch M, Nick JA, Illek B, Wallenburg JC, Sorscher EJ, Amaral MD, Beekman JM, Naren AP, Bridges RJ, Thomas PJ, Cutting G, Rowe S, Durmowicz AG, Mense M, Boeck KD, Skach W, Penland C, Joseloff E, Bihler H, Mahoney J, Borowitz D, Tuggle KL.

J Cyst Fibros. 2019 Jan;18(1):22-34. doi: 10.1016/j.jcf.2018.05.004. Epub 2018 Jun 20. Review.

12.

Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial.

Ratjen F, Klingel M, Black P, Powers MR, Grasemann H, Solomon M, Sagel SD, Donaldson SH, Rowe SM, Rosenfeld M.

Am J Respir Crit Care Med. 2018 Aug 15;198(4):526-528. doi: 10.1164/rccm.201802-0243LE. No abstract available.

13.

Rearrangements under confinement lead to increased binding energy of Synaptotagmin-1 with anionic membranes in Mg2+ and Ca2.

Gruget C, Coleman J, Bello O, Krishnakumar SS, Perez E, Rothman JE, Pincet F, Donaldson SH Jr.

FEBS Lett. 2018 May;592(9):1497-1506. doi: 10.1002/1873-3468.13040. Epub 2018 Apr 10.

14.

Molecular Imaging of Cholesterol and Lipid Distributions in Model Membranes.

Donaldson SH Jr, de Aguiar HB.

J Phys Chem Lett. 2018 Apr 5;9(7):1528-1533. doi: 10.1021/acs.jpclett.8b00235. Epub 2018 Mar 12.

PMID:
29521507
15.

Hypertonic saline has a prolonged effect on mucociliary clearance in adults with cystic fibrosis.

Trimble AT, Whitney Brown A, Laube BL, Lechtzin N, Zeman KL, Wu J, Ceppe A, Waltz D, Bennett WD, Donaldson SH.

J Cyst Fibros. 2018 Sep;17(5):650-656. doi: 10.1016/j.jcf.2018.01.001. Epub 2018 Jan 20.

16.

Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation.

Trimble AT, Donaldson SH.

J Cyst Fibros. 2018 Mar;17(2):e13-e16. doi: 10.1016/j.jcf.2017.09.006. Epub 2017 Oct 24.

PMID:
29079142
17.

Homogeneity of Aerosol Deposition and Mucociliary Clearance are Improved Following Ivacaftor Treatment in Cystic Fibrosis.

Bennett WD, Zeman KL, Laube BL, Wu J, Sharpless G, Mogayzel PJ Jr, Donaldson SH.

J Aerosol Med Pulm Drug Deliv. 2018 Aug;31(4):204-211. doi: 10.1089/jamp.2017.1388. Epub 2017 Oct 16.

18.

Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.

Donaldson SH, Pilewski JM, Griese M, Cooke J, Viswanathan L, Tullis E, Davies JC, Lekstrom-Himes JA, Wang LT; VX11-661-101 Study Group.

Am J Respir Crit Care Med. 2018 Jan 15;197(2):214-224. doi: 10.1164/rccm.201704-0717OC.

19.

Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR.

Donaldson SH, Solomon GM, Zeitlin PL, Flume PA, Casey A, McCoy K, Zemanick ET, Mandagere A, Troha JM, Shoemaker SA, Chmiel JF, Taylor-Cousar JL.

J Cyst Fibros. 2017 May;16(3):371-379. doi: 10.1016/j.jcf.2017.01.009. Epub 2017 Feb 13.

20.

A Trans-Nasal Aerosol Delivery Device for Efficient Pulmonary Deposition.

Zeman KL, Balcazar JR, Fuller F, Donn KH, Boucher RC, Bennett WD, Donaldson SH.

J Aerosol Med Pulm Drug Deliv. 2017 Aug;30(4):223-229. doi: 10.1089/jamp.2016.1333. Epub 2017 Feb 3.

21.

Effects of inhaled high-molecular weight hyaluronan in inflammatory airway disease.

Lamas A, Marshburn J, Stober VP, Donaldson SH, Garantziotis S.

Respir Res. 2016 Oct 3;17(1):123.

22.

Hydrator Therapies for Chronic Bronchitis. Lessons from Cystic Fibrosis.

Bennett WD, Henderson AG, Donaldson SH.

Ann Am Thorac Soc. 2016 Apr;13 Suppl 2:S186-90. doi: 10.1513/AnnalsATS.201509-652KV. Review.

23.

Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis.

Davis SD, Ratjen F, Brumback LC, Johnson RC, Filbrun AG, Kerby GS, Panitch HB, Donaldson SH, Rosenfeld M; ISIS Study Group.

J Cyst Fibros. 2016 May;15(3):386-91. doi: 10.1016/j.jcf.2015.10.007. Epub 2015 Nov 4.

24.

Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis.

Gaggar A, Chen J, Chmiel JF, Dorkin HL, Flume PA, Griffin R, Nichols D, Donaldson SH.

J Cyst Fibros. 2016 Mar;15(2):227-33. doi: 10.1016/j.jcf.2015.07.009. Epub 2015 Aug 28.

25.

Correlating steric hydration forces with water dynamics through surface force and diffusion NMR measurements in a lipid-DMSO-H2O system.

Schrader AM, Donaldson SH Jr, Song J, Cheng CY, Lee DW, Han S, Israelachvili JN.

Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10708-13. doi: 10.1073/pnas.1512325112. Epub 2015 Aug 10.

26.

Effects of Surfactants and Polyelectrolytes on the Interaction between a Negatively Charged Surface and a Hydrophobic Polymer Surface.

Rapp MV, Donaldson SH Jr, Gebbie MA, Gizaw Y, Koenig P, Roiter Y, Israelachvili JN.

Langmuir. 2015 Jul 28;31(29):8013-21. doi: 10.1021/acs.langmuir.5b01781. Epub 2015 Jul 15.

27.

Real-time intermembrane force measurements and imaging of lipid domain morphology during hemifusion.

Lee DW, Kristiansen K, Donaldson SH Jr, Cadirov N, Banquy X, Israelachvili JN.

Nat Commun. 2015 May 26;6:7238. doi: 10.1038/ncomms8238.

28.

Duration of action of hypertonic saline on mucociliary clearance in the normal lung.

Bennett WD, Wu J, Fuller F, Balcazar JR, Zeman KL, Duckworth H, Donn KH, O'Riordan TG, Boucher RC, Donaldson SH.

J Appl Physiol (1985). 2015 Jun 15;118(12):1483-90. doi: 10.1152/japplphysiol.00404.2014. Epub 2015 Apr 24.

29.

Novel outcome measures for clinical trials in cystic fibrosis.

Tiddens HAWM, Puderbach M, Venegas JG, Ratjen F, Donaldson SH, Davis SD, Rowe SM, Sagel SD, Higgins M, Waltz DA.

Pediatr Pulmonol. 2015 Mar;50(3):302-315. doi: 10.1002/ppul.23146. Epub 2014 Dec 30. Review.

30.

Hydrophobic, electrostatic, and dynamic polymer forces at silicone surfaces modified with long-chain bolaform surfactants.

Rapp MV, Donaldson SH Jr, Gebbie MA, Das S, Kaufman Y, Gizaw Y, Koenig P, Roiter Y, Israelachvili JN.

Small. 2015 May 6;11(17):2058-68. doi: 10.1002/smll.201402229. Epub 2014 Dec 15.

31.

Developing a general interaction potential for hydrophobic and hydrophilic interactions.

Donaldson SH Jr, Røyne A, Kristiansen K, Rapp MV, Das S, Gebbie MA, Lee DW, Stock P, Valtiner M, Israelachvili J.

Langmuir. 2015 Feb 24;31(7):2051-64. doi: 10.1021/la502115g. Epub 2014 Aug 18.

PMID:
25072835
32.

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.

Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, Sagel SD, Khan U, Mayer-Hamblett N, Van Dalfsen JM, Joseloff E, Ramsey BW; GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network.

Am J Respir Crit Care Med. 2014 Jul 15;190(2):175-84. doi: 10.1164/rccm.201404-0703OC.

33.

Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure.

Henderson AG, Ehre C, Button B, Abdullah LH, Cai LH, Leigh MW, DeMaria GC, Matsui H, Donaldson SH, Davis CW, Sheehan JK, Boucher RC, Kesimer M.

J Clin Invest. 2014 Jul;124(7):3047-60. doi: 10.1172/JCI73469. Epub 2014 Jun 2.

34.

Hypertonic saline for cystic fibrosis: worth its salt?

Goralski JL, Donaldson SH.

Expert Rev Respir Med. 2014 Jun;8(3):267-9. doi: 10.1586/17476348.2014.896203. Epub 2014 Mar 26.

PMID:
24666113
35.

A biophysical basis for mucus solids concentration as a candidate biomarker for airways disease.

Hill DB, Vasquez PA, Mellnik J, McKinley SA, Vose A, Mu F, Henderson AG, Donaldson SH, Alexis NE, Boucher RC, Forest MG.

PLoS One. 2014 Feb 18;9(2):e87681. doi: 10.1371/journal.pone.0087681. eCollection 2014. Erratum in: PLoS One. 2014;9(5):e97980.

36.

The intersection of interfacial forces and electrochemical reactions.

Israelachvili JN, Kristiansen K, Gebbie MA, Lee DW, Donaldson SH Jr, Das S, Rapp MV, Banquy X, Valtiner M, Yu J.

J Phys Chem B. 2013 Dec 27;117(51):16369-87. doi: 10.1021/jp408144g. Epub 2013 Nov 22. Review.

PMID:
24229092
37.

Asymmetric electrostatic and hydrophobic-hydrophilic interaction forces between mica surfaces and silicone polymer thin films.

Donaldson SH Jr, Das S, Gebbie MA, Rapp M, Jones LC, Roiter Y, Koenig PH, Gizaw Y, Israelachvili JN.

ACS Nano. 2013 Nov 26;7(11):10094-104. doi: 10.1021/nn4050112. Epub 2013 Oct 23.

38.

Multicenter intestinal current measurements in rectal biopsies from CF and non-CF subjects to monitor CFTR function.

Clancy JP, Szczesniak RD, Ashlock MA, Ernst SE, Fan L, Hornick DB, Karp PH, Khan U, Lymp J, Ostmann AJ, Rezayat A, Starner TD, Sugandha SP, Sun H, Quinney N, Donaldson SH, Rowe SM, Gabriel SE.

PLoS One. 2013 Sep 10;8(9):e73905. doi: 10.1371/journal.pone.0073905. eCollection 2013.

39.

New pulmonary therapies directed at targets other than CFTR.

Donaldson SH, Galietta L.

Cold Spring Harb Perspect Med. 2013 Jun 1;3(6). pii: a009787. doi: 10.1101/cshperspect.a009787. Review.

40.

Comparison of 133 xenon ventilation equilibrium scan (XV) and 99m technetium transmission (TT) scan for use in regional lung analysis by 2D gamma scintigraphy in healthy and cystic fibrosis lungs.

Zeman KL, Wu J, Donaldson SH, Bennett WD.

J Aerosol Med Pulm Drug Deliv. 2013 Apr;26(2):94-100. doi: 10.1089/jamp.2012.0982. Epub 2013 Feb 19.

41.

Hydrophobic interactions modulate self-assembly of nanoparticles.

Sánchez-Iglesias A, Grzelczak M, Altantzis T, Goris B, Pérez-Juste J, Bals S, Van Tendeloo G, Donaldson SH Jr, Chmelka BF, Israelachvili JN, Liz-Marzán LM.

ACS Nano. 2012 Dec 21;6(12):11059-65. doi: 10.1021/nn3047605. Epub 2012 Dec 5.

PMID:
23186074
42.

Progress in cystic fibrosis and the CF Therapeutics Development Network.

Rowe SM, Borowitz DS, Burns JL, Clancy JP, Donaldson SH, Retsch-Bogart G, Sagel SD, Ramsey BW.

Thorax. 2012 Oct;67(10):882-90. doi: 10.1136/thoraxjnl-2012-202550.

43.

Hydrophobic forces, electrostatic steering, and acid-base bridging between atomically smooth self-assembled monolayers and end-functionalized PEGolated lipid bilayers.

Valtiner M, Donaldson SH Jr, Gebbie MA, Israelachvili JN.

J Am Chem Soc. 2012 Jan 25;134(3):1746-53. doi: 10.1021/ja209653n. Epub 2012 Jan 11.

PMID:
22176530
44.

General hydrophobic interaction potential for surfactant/lipid bilayers from direct force measurements between light-modulated bilayers.

Donaldson SH Jr, Lee CT Jr, Chmelka BF, Israelachvili JN.

Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):15699-704. doi: 10.1073/pnas.1112411108. Epub 2011 Sep 6.

45.

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, De Boeck K, Donaldson SH, Dorkin HL, Dunitz JM, Durie PR, Jain M, Leonard A, McCoy KS, Moss RB, Pilewski JM, Rosenbluth DB, Rubenstein RC, Schechter MS, Botfield M, Ordoñez CL, Spencer-Green GT, Vernillet L, Wisseh S, Yen K, Konstan MW.

Thorax. 2012 Jan;67(1):12-8. doi: 10.1136/thoraxjnl-2011-200393. Epub 2011 Aug 8.

46.

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.

Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordoñez CL, Campbell PW, Ashlock MA, Ramsey BW.

N Engl J Med. 2010 Nov 18;363(21):1991-2003. doi: 10.1056/NEJMoa0909825.

47.

Analysis of the bacterial communities present in lungs of patients with cystic fibrosis from American and British centers.

Stressmann FA, Rogers GB, Klem ER, Lilley AK, Donaldson SH, Daniels TW, Carroll MP, Patel N, Forbes B, Boucher RC, Wolfgang MC, Bruce KD.

J Clin Microbiol. 2011 Jan;49(1):281-91. doi: 10.1128/JCM.01650-10. Epub 2010 Nov 10.

48.

Direct measurement of double-layer, van der Waals, and polymer depletion attraction forces between supported cationic bilayers.

Anderson TH, Donaldson SH, Zeng H, Israelachvili JN.

Langmuir. 2010 Sep 21;26(18):14458-65. doi: 10.1021/la1020687.

PMID:
20735021
49.

Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively?

Tiddens HA, Donaldson SH, Rosenfeld M, Paré PD.

Pediatr Pulmonol. 2010 Feb;45(2):107-17. doi: 10.1002/ppul.21154. Review.

PMID:
20082341
50.

SPLUNC1 regulates airway surface liquid volume by protecting ENaC from proteolytic cleavage.

Garcia-Caballero A, Rasmussen JE, Gaillard E, Watson MJ, Olsen JC, Donaldson SH, Stutts MJ, Tarran R.

Proc Natl Acad Sci U S A. 2009 Jul 7;106(27):11412-7. doi: 10.1073/pnas.0903609106. Epub 2009 Jun 18. Erratum in: Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):15091.

Supplemental Content

Loading ...
Support Center